HC Wainwright & Co. Reiterates Buy on Journey Medical, Maintains $13 Price Target

Benzinga · 1d ago
HC Wainwright & Co. analyst Brandon Folkes reiterates Journey Medical (NASDAQ:DERM) with a Buy and maintains $13 price target.